Researchers at the University of Essex have used artificial intelligence to design "intrabodies" that can operate inside human cells to target disease-related proteins [1].
This development is significant because traditional antibodies typically work outside of cells, whereas these AI-designed molecules can enter the intracellular environment to address the root causes of neurodegeneration [2].
The international team developed these tiny antibody-derived molecules to target proteins implicated in several severe conditions [1]. The research focuses on creating therapeutic pathways for Alzheimer’s, Parkinson’s, Huntington’s disease, and motor neurone disease [2].
By utilizing AI, the scientists were able to engineer these intrabodies to function specifically within the cell [3]. This allows the molecules to seek out and bind to the toxic proteins that characterize these diseases, a process that has previously been difficult to achieve with standard medical treatments [1].
Motor neurone disease and other neurodegenerative disorders often involve the accumulation of misfolded proteins inside neurons [2]. The AI-designed intrabodies are intended to intercept these proteins before they can cause widespread cellular damage [3].
The project represents a collaboration between the University of Essex and other international partners [1]. The team aimed to overcome the biological barriers that prevent most antibodies from reaching their targets inside the cell membrane [2].
While the research is in the development stage, the ability to customize molecules via AI allows for more precise targeting of specific protein strains [3]. This precision could reduce off-target effects and increase the efficacy of future treatments for brain-related disorders [1].
“AI-designed molecules can enter the intracellular environment to address the root causes of neurodegeneration.”
The shift toward intracellular targeting marks a transition in neurology from managing external symptoms to addressing internal cellular toxicity. If these AI-designed intrabodies prove effective in clinical trials, it would validate the use of generative AI in protein engineering to treat diseases that were previously considered unreachable by the immune system's natural mechanisms.
